All companies
Visit website
SARCOMATRIX
OperatingSarcomatrix Therapeutics Corporation
Healthcare · Founded 2022
Pre-revenue and pre-commercialization stages of development
Post-money valuation ⓘ
$14.3M
As of Jul 2024 · from Sarcomatrix Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$49,170
Across 2 rounds since 2024
Latest share price
$2.50
Reg CF Offering (2024) offering price
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its source$0
−$2.1M
2022
$0
−$103K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$2,078,929
-$103,375
Taxes paid
$0
$0
Balance sheet
Cash
$0
$36,803
Accounts receivable
$0
$0
Total assets
$0
$36,803
Short-term debt
$0
$18,894
Long-term debt
$0
$113,330
Total liabilities
$0
$132,224
Other
Headcount
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$14.3M
post-money
Sarcomatrix Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.2M
Raised $49.2K / $1.2MInvestors 20Post-money $14.3M
Reg CF annual-report compliance
Delinquent
Filed 0 of 2 annual reports (FY2024–FY2025)
Missing: 2024, 2025
20 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002017651Share price $2.50
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.